The result marks the third consecutive grant cycle in which NRG Oncology has achieved the exceptional score. In the NCI review framework, such scores reflect a judgment that a research program has outstanding scientific merit, a clear potential for meaningful clinical impact, and the infrastructure needed to deliver its proposed work. For a cooperative clinical research group, the evaluation encompasses far more than laboratory discovery. Reviewers assess the organization’s ability to design statistically rigorous trials, recruit patients across multiple institutions, manage complex data, integrate biological specimens, monitor treatment safety, and translate results into clinical practice. NRG Oncology’s renewal therefore represents both continued federal investment and a strong endorsement of its research model.

“This is the third grant cycle in a row that NRG Oncology has received an exceptional score during the grant application review process,” said Quynh Thu Le, MD, an NRG Oncology Group Chair, Chair of the Department of Radiation Oncology at Stanford University, and Co-Director of the Radiation Biology Program at the Stanford Cancer Institute. She also chairs the NRG Oncology Board of Directors. Le described the recognition as an acknowledgment of the collective effort required to improve outcomes for people affected by cancer. In modern oncology, advances rarely result from a single institution or discipline. They emerge from coordinated studies that combine clinical expertise with molecular biology, imaging, radiation science, surgery, pathology, biostatistics, and patient-centered research.

NRG Oncology’s renewed mission focuses on adult patients with sex-specific malignancies, including breast, gynecologic, and prostate cancers, as well as people with localized or locally advanced cancers. These diseases occupy an important space in cancer research because treatment decisions often depend on the biological behavior of a tumor, its anatomical extent, the risk of recurrence, and the patient’s individual health profile. Localized cancers may be curable, but unnecessary treatment can cause lasting harm, including infertility, cardiovascular complications, neurological effects, sexual dysfunction, or chronic tissue damage. NRG Oncology’s trials seek to identify which patients require intensive treatment, which can safely receive less, and how emerging therapies can be integrated without compromising disease control.

A central feature of the group’s scientific strategy is risk stratification, the process of separating patients into clinically meaningful categories according to the likelihood that their cancer will return or progress. Researchers use conventional clinical variables, such as tumor stage and grade, alongside biomarkers that reveal genetic, molecular, or immune characteristics of the disease. This information can be incorporated into algorithms that guide treatment intensity and duration. For example, a molecular signature may indicate that a tumor is biologically aggressive even when it appears limited on imaging, or it may identify a patient whose cancer is unlikely to benefit from prolonged therapy. Testing these approaches in prospective, multi-institutional trials is essential because an algorithm must demonstrate reproducible clinical benefit, not merely statistical association.

The group is also applying emerging knowledge in therapeutics to early- and late-phase clinical trials. These studies may evaluate targeted medicines designed to interfere with specific signaling pathways, immunotherapies that alter the interaction between tumors and the immune system, or combinations intended to overcome treatment resistance. In localized and locally advanced disease, the timing of systemic therapy can be as important as the drug itself. Investigators may test whether treatment given before surgery or radiation can shrink a tumor, eliminate microscopic disease, or provide an early indication of sensitivity. Other trials examine whether maintenance therapy can prevent recurrence after definitive treatment. Because these questions involve both survival and long-term quality of life, they require carefully controlled designs and prolonged follow-up.

Radiation oncology, surgery, and medical imaging are additional areas in which NRG Oncology is testing new technologies through multi-institutional research. Advances in image guidance can allow clinicians to locate tumors and vulnerable organs with greater precision, while modern radiation techniques can shape dose distributions around complex anatomy. Surgical trials may evaluate less invasive procedures or strategies that preserve normal function without reducing cancer control. Imaging research can explore whether functional or molecular scans provide information beyond standard anatomical pictures. Yet technological sophistication alone does not establish clinical value. NRG Oncology’s randomized trials are intended to determine whether these innovations improve survival, reduce toxic effects, enhance quality of life, or make treatment more efficient and accessible.

“The overall impact of NRG Oncology is high, with the potential to markedly enhance the quality of clinical trials based on the outstanding progress during the current funding period,” NCI grant reviewers wrote, highlighting the organization’s continued emphasis on science-driven and molecularly guided therapeutic studies. Their assessment also recognized the group’s focus on sex-driven, rare, and localized or locoregionally advanced cancers. These categories include diseases for which individual hospitals may struggle to enroll enough participants to answer important questions. By connecting hundreds of centers, cooperative groups can assemble patient populations large enough to compare treatments reliably, investigate uncommon tumor features, and identify differences in outcomes across diverse communities.

The scale of that network is central to the organization’s work. NRG Oncology was founded in 2012 through the integration of research programs associated with the National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group. It now brings together more than 1,300 research sites worldwide, with most located in the United States and Canada. Its investigators include medical and radiation oncologists, surgeons, physicists, pathologists, statisticians, imaging specialists, and other experts. Patient advocates also participate in the research process, helping shape questions that matter to people living with cancer and drawing attention to outcomes that may not be captured by survival statistics alone. The organization’s studies are supported primarily by NCI grants and form part of the federally funded NCTN, one of the world’s largest publicly supported infrastructures for cancer clinical research.

Robert Mannel, MD, an NRG Oncology Group Chair and Director of the Stephenson Cancer Center at the University of Oklahoma, emphasized that the renewal depended on the contributions of member sites, researchers, advocates, staff, and—most importantly—the patients who enroll in trials. Norman Wolmark, MD, the organization’s grant contact principal investigator and a professor of surgery at the University of Pittsburgh, said the exceptional score and the strengths identified by reviewers indicate that NRG Oncology is positioned to build on its recent achievements. Over the next six years, the group will use the new funding to pursue trials intended to make cancer treatment more precise: matching therapies to tumor biology, limiting unnecessary exposure, improving the use of radiation and surgery, and producing evidence that can move rapidly from research centers into everyday care. For patients, the significance of the award will ultimately be measured not by the grant itself, but by whether the studies it enables help more people live longer and with fewer consequences of cancer and its treatment.

Subject of Research: NRG Oncology’s federally funded cancer clinical-trial and translational-research program, including molecularly guided treatment, risk stratification, radiation oncology, surgery, imaging, and sex-specific and localized or locally advanced cancers.

News Publication Date: Not provided. The renewed six-year grant cycle began March 1, 2026.

Web References: NRG Oncology, www.nrgoncology.org

Keywords: NRG Oncology, National Cancer Institute, National Clinical Trials Network, cancer research, clinical trials, oncology, molecular biomarkers, risk stratification, radiation oncology, breast cancer, gynecologic cancer, prostate cancer, localized cancer, translational research

The overarching goal of the Sarcoma Subcommittee is to cultivate a comprehensive sarcoma program within NRG’s project portfolio. By doing so, NRG aims to enhance the resources available to its investigators and foster collaboration with the Children’s Oncology Group, particularly in treating adolescent and young adult (AYA) patients. This dual focus underscores a commitment not only to adult sarcoma patients but also to improving outcomes for younger demographics who may experience different therapeutic pathways and challenges. Collaborations with other National Clinical Trials Network (NCTN) adult groups are also prioritized, promoting a unified front in advancing sarcoma research across institutions.

Leadership within the new Sarcoma Subcommittee is marked by the appointment of notable figures such as Dr. Dian Wang, who has been designated as Chair of the group. A distinguished professor of Radiation Oncology at Rush University Medical Center, Dr. Wang comes with a wealth of experience, specifically in radiation therapy for sarcoma and genitourinary cancers. His leadership record includes orchestrating national cooperative trials that leverage novel therapeutic strategies against soft tissue sarcoma, showcasing his credentials and commitment to progressing treatment protocols.

Dr. Wang’s track record includes guiding his institution to achieve significant involvement in pivotal trials, particularly NRG-DT001, which investigates neoadjuvant navetemadlin in combination with preoperative radiotherapy for wild-type p53 soft tissue sarcomas. Moreover, his role in pioneering the first image-guided radiotherapy (IGRT) study within the historically significant RTOG (now RTOG Foundation) further amplifies his qualifications for leading this vital subcommittee. His passion for mentoring the next generation of investigators also aligns seamlessly with NRG’s broader mission to cultivate talent within the oncology research domain.

Joining him in leadership are Dr. William Tseng and Dr. Brian A. Van Tine, both appointed as Vice-Chairs of the Sarcoma Subcommittee. Dr. Tseng, an associate professor of surgery at the City of Hope Medical Center, brings robust experience in translational sarcoma research. His previous roles include co-leading the Sarcoma and Melanoma Disease Team and contributing to several international collaborative efforts that have resulted in significant findings and refined treatment guidelines. His advocacy work with the Sarcoma Alliance further positions him to contribute uniquely to the committee’s objectives—aiming not only at clinical outcomes but also integrating patient perspectives into research applications.

Dr. Van Tine serves as the Director of Phase I Clinical Trials and the Sarcoma Program Director at Washington University School of Medicine. He is recognized nationally for his expertise in implementing innovative therapeutic strategies in sarcoma and is deeply involved in trials targeting adolescent and young adult populations. His experience as an active member of the Sarcoma Working Group at NRG, coupled with his national leadership in collaborative initiatives, fortifies his role in shaping the future of sarcoma research.

In conjunction with the establishment of the Sarcoma Subcommittee, NRG Oncology has also appointed Dr. Clifton (Dave) Fuller as the Vice-Chair of its Imaging Committee. This committee plays a critical role in optimizing imaging methodologies within clinical trials, ensuring that both standard and novel imaging techniques support the efficacy of trial endpoints. Dr. Fuller, a leading figure in Radiation Oncology at The University of Texas MD Anderson Cancer Center, has dedicated his career to advancing the integration of imaging science into cancer treatment.

His expertise, particularly in MR-guided radiotherapy (MRgRT), has set new standards for implementing imaging technology in effective cancer therapeutic practices. Dr. Fuller’s leadership in pioneering the U.S. treatment employing advanced MR-LinAc platforms exemplifies his commitment to revolutionizing how imaging can enhance treatment workflows and improve care standards for cancer patients.

As NRG Oncology continues to expand its reach within cancer research, these newly forged leadership roles—both in the Sarcoma Subcommittee and the Imaging Committee—offer a glimpse into the future of sarcoma and imaging research. The collaborative efforts of these appointed experts promise to lead to ground-breaking advancements, potentially transforming the landscape of sarcoma management and treatment protocols as they remain committed to improving outcomes for patients.

The establishment of these committees illustrates NRG’s dynamic approach to oncological research, specifically targeting the multifaceted challenges posed by sarcoma. By fostering a culture of collaboration and innovation, NRG Oncology is not only enhancing its research portfolio but also ensuring that it remains at the forefront of improving patient care through evidence-driven clinical research.

As a nonprofit entity integrated into the massive network of the National Cancer Institute, NRG Oncology thrives on collecting grants and funding to facilitate its ambitious research agenda. The institution encompasses over 1,300 research sites globally, focusing on various malignancies. NRG’s infusion of expert leadership through initiatives like the Sarcoma Subcommittee and the Imaging Committee conveys the organization’s commitment to delivering pioneering clinical trials that aim for practice-changing outcomes for patients.

From leveraging the expertise of renowned oncologists to ensuring comprehensive collaborations across institutions, the new developments at NRG Oncology underline the collective goal of improving cancer research and refining treatment methodologies. By focusing on the unique challenges posed by sarcoma and harnessing advanced imaging techniques, NRG is poised to make significant strides in oncology research, thereby advancing the standard of care available to cancer patients.

With the establishment of the Sarcoma Subcommittee and the strategic appointments made, NRG Oncology has laid the groundwork for a future rich in innovation and improvement. Through these targeted efforts, the organization seeks to illuminate the complexities of sarcoma research and treatment, laying the foundation for better outcomes for all patients grappling with this challenging disease.

As they embark on this new chapter, NRG Oncology looks ahead with hope and optimism, eager to see how these initiatives will unfold. The collective expertise, passion, and commitment of those involved will undoubtedly stimulate a wave of research advancements, capturing the attention of the scientific community while ultimately providing tangible benefits to patients navigating their cancer journeys.

Subject of Research: Sarcoma and Imaging in Cancer Treatment
Article Title: NRG Oncology Expands Its Horizons with New Sarcoma Subcommittee and Imaging Leadership
News Publication Date: [Date Not Provided]
Web References: [None Provided]
References: [None Provided]
Image Credits: [None Provided]

Keywords: NRG Oncology, Sarcoma Subcommittee, Clinical Trials, Cancer Research, Imaging Committee